Associations Between the Genetic Polymorphisms of Osteopontin Promoter and Susceptibility to Cancer in Chinese Population: A Meta-Analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Aug 13

PMID 26267616

Citations 3

Authors

Yulan Liu

Hongbo Lei

Jixiang Zhang

Jun Wang

Kui Li

Weiguo Dong

Affiliations

Soon will be listed here.

Abstract

Background And Aim: Several studies have been conducted to examine the associations between osteopontin (OPN) promoter gene SPP1 polymorphisms with human cancers in Chinese population, but the results remain inconsistent. The aim of this meta-analysis is to clarify the associations between SPP1 polymorphisms and cancer susceptibility.

Methods: All eligible case-control studies published up to March 2015 were identified by searching PubMed, Web of Science, Embase, and Cochrane Library without language restrictions. Pooled odds ratio (OR) and 95% confidence interval (95% CI) were calculated using fixed- or random-effect model.

Results: A total of 11 case-control studies were included; of those, there were eleven studies (3130 cases and 3828 controls) for -443T>C polymorphism, ten studies (3019 cases and 3615 controls) for -156G>GG polymorphism, eight studies (2258 cases and 2846 controls) for -66T>G polymorphism. Overall, no evidence indicated that the -443 T>C polymorphism was associated with cancer risk (OR = 0.93, 95%CI 0.62-1.38 for dominant model, OR = 1.06, 95%CI 0.73-1.55 for recessive model, OR = 0.88, 95%CI 0.62-1.26 for CT vs TT model, OR = 1.03, 95%CI 0.61-1.73 for CC vs TT model). While, a significantly increase risk was found for -156 G>GG polymorphism (OR = 1.22, 95%CI 1.10-1.35 for dominant model, OR = 1.25, 95%CI 1.10-1.41 for recessive model, OR = 1.18, 95%CI 1.06-1.32 for GGG vs GG model, OR = 1.35, 95%CI 1.09-1.68 for GGGG vs GG model). For -66T>G polymorphism, we found a decrease risk of cancer (OR = 0.84, 95% CI 0.71-0.98 for dominant model), but this result changed (OR = 0.93, 95% CI 0.77-1.12 for dominant model) when we excluded a study.

Conclusion: This meta-analysis suggests that in Chinese population the -156G>GG polymorphism of SPP1 might be a risk factor for human cancers, while -443T>C mutation is not associated with cancer risk. For -66T>G polymorphism, it may be a protective factor for human cancers.

Citing Articles

Common Variants in Osteopontin and Genes as Predictors of Treatment Outcome in Radiotherapy and Chemoradiotherapy for Non-Small Cell Lung Cancer.

Galecki S, Gdowicz-Klosok A, Deja R, Maslyk B, Giglok M, Suwinski R Cells. 2023; 12(23).

PMID: 38067149 PMC: 10706014. DOI: 10.3390/cells12232721.

Genetic Modifiers of Duchenne Muscular Dystrophy in Chinese Patients.

Chen M, Wang L, Li Y, Chen Y, Zhang H, Zhu Y Front Neurol. 2020; 11:721.

PMID: 32849198 PMC: 7403400. DOI: 10.3389/fneur.2020.00721.

Association between promoter polymorphisms of OPN gene and cancer risk: a meta-analysis.

Liu J, He C, Yuan Q, Wang Z, Xing C, Yuan Y Onco Targets Ther. 2016; 9:87-97.

PMID: 26766914 PMC: 4699542. DOI: 10.2147/OTT.S94606.

References

Chen Y, Liu H, Wu W, Li Y, Li J . Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis. J Exp Clin Cancer Res. 2013; 32:45. PMC: 3728114. DOI: 10.1186/1756-9966-32-45. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Fan Y, Zhang X, Yang Z, Sun X, Li S, Zhong L . The polymorphisms of osteopontin gene and plasma osteopontin protein levels with susceptibility to colorectal carcinoma. DNA Cell Biol. 2013; 32(10):594-600. DOI: 10.1089/dna.2013.2090. View

Hudson T . Genome variation and personalized cancer medicine. J Intern Med. 2013; 274(5):440-50. DOI: 10.1111/joim.12097. View

Wang J, Nong L, Tang Y, Wei Y, Yang F, Wang C . Correlation between OPN gene polymorphisms and the risk of nasopharyngeal carcinoma. Med Oncol. 2014; 31(7):20. DOI: 10.1007/s12032-014-0020-x. View

Dudemaine P, Thibault C, Alain K, Bissonnette N . Genetic variations in the SPP1 promoter affect gene expression and the level of osteopontin secretion into bovine milk. Anim Genet. 2014; 45(5):629-40. DOI: 10.1111/age.12176. View

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

10.

Rangaswami H, Bulbule A, Kundu G . Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006; 16(2):79-87. DOI: 10.1016/j.tcb.2005.12.005. View

11.

Hashiguchi Y, Tsuda H, Bandera C, Nishimura S, Inoue T, Kawamura N . Comparison of osteopontin expression in endometrioid endometrial cancer and ovarian endometrioid cancer. Med Oncol. 2006; 23(2):205-12. DOI: 10.1385/MO:23:2:205. View

12.

Wu C, Wu M, Chiang E, Wu C, Chen Y, Chen C . Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut. 2006; 56(6):782-9. PMC: 1954839. DOI: 10.1136/gut.2006.109868. View

13.

Chang Y, Kim H, Chang J, Ahn C, Kim S, Kim S . Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer. 2007; 57(3):373-80. DOI: 10.1016/j.lungcan.2007.04.005. View

14.

Mirza M, Shaughnessy E, Hurley J, Vanpatten K, Pestano G, He B . Osteopontin-c is a selective marker of breast cancer. Int J Cancer. 2007; 122(4):889-97. DOI: 10.1002/ijc.23204. View

15.

Kato R, Momiyama Y, Ohmori R, Tanaka N, Taniguchi H, Arakawa K . Prognostic significance of plasma osteopontin levels in patients undergoing percutaneous coronary intervention. Circ J. 2008; 73(1):152-7. DOI: 10.1253/circj.cj-08-0687. View

16.

Schultz J, Lorenz P, Ibrahim S, Kundt G, Gross G, Kunz M . The functional -443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor. Mol Carcinog. 2008; 48(1):14-23. DOI: 10.1002/mc.20452. View

17.

Alain K, Karrow N, Thibault C, St-Pierre J, Lessard M, Bissonnette N . Osteopontin: an early innate immune marker of Escherichia coli mastitis harbors genetic polymorphisms with possible links with resistance to mastitis. BMC Genomics. 2009; 10:444. PMC: 2761946. DOI: 10.1186/1471-2164-10-444. View

18.

Chen J, Wu Q, Lu Y, Xu T, Huang Y, Ribas J . SPP1 promoter polymorphisms and glioma risk in a Chinese Han population. J Hum Genet. 2010; 55(7):456-61. DOI: 10.1038/jhg.2010.48. View

19.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

20.

Weber G, Lett G, Haubein N . Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer. 2010; 103(6):861-9. PMC: 2966627. DOI: 10.1038/sj.bjc.6605834. View